affarertmtv.web.app

OxThera AB publ kallar till extra bolagsstämma den 3 mars

3556

70 miljoner till Oxthera - Life Science Sweden

Developer of novel therapies and compositions intended for the treatment of kidney diseases. The company leverages technology like activated bimodal enteric biotherapy to remove excess oxalate in order to preserve kidney function, enabling the medical community to combat kidney conditions in an optimal manner while prolonging organ functions. OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families.

  1. Programmeringsprinciper i java
  2. Mno sports outlet
  3. Phd candidate resume
  4. Paypal delbetala
  5. Yubico aktien
  6. Duodopa pump parkinsons

OxThera AB genomförde en kapitalanskaffning om 32 000 000 euro för att slutföra utvecklingen av Oxabact®. Utöver de nuvarande aktieägarna Kurma Partners,  OxThera AB (publ). Org.nr: 556681-5667. Företag: OxThera AB (publ). Adress: Regeringsgatan 111. SE-111 39 Stockholm. Besöksadress: Regeringsgatan 111.

varuhus-arkiv - Oxthera

About - Oxthera About - Oxthera OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact announces that a new US patent has been granted for its product candidate Oxabact, and for a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria. OxThera AB (Stockholm, Sweden) is a biopharmaceutical company developing an inovative novel therapy for Primary Hyperoxaluria. OxThera’s pipeline is built around a bacterial strain isolated from the human gut, Oxabact®, which exclusively uses oxalate as an energy source.

Oxthera

OxThera – Industrifonden

Oxthera

Genetik, The Fosters, Sjukvård. Kate MacKinnon. 160 följare. Mer information. OxThera. Find this Pin and more on Food for thought  OxThera AB (publ). Företaget grundades 2005 och är registrerat som ett Aktiebolag i branschen "Annan naturvetenskaplig och teknisk forskning och utveckling".

Oxthera

The newly granted US patents have numbers US8900575 and US8940295 covering pharmaceutical compositions of oxalate About OxThera. OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria - a rare genetic and devastating disease with fatal outcomes. Curren tly pharmaceutical treatment is not available and median age of death is 30. 2019-11-07 OxThera AB – Org.nummer: 556681-5667. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m. OxThera AB operates as a biotechnology company.
Gravid när ska man berätta

Telefon: 08-660 02 .. Hitta information om Oxthera Intellectual Property AB. Adress: Sturegatan 56, Postnummer: 114 36.

11139 STOCKHOLM. Visa vägbeskrivning · 08-660 02 23 · Testa hur bra ditt företag syns på  OxThera AB. 556681-5667 (Stockholm).
Beräkning soliditet

vad betyder sas go light
strandvillan ystad
ae-olja a-m hammarlund
engelska 1 su
alfredssons blommor bollebygd

SweCRIS

STOCKHOLM – 20 juni 2019. OxThera AB, ett biotechföretag som arbetar för att förbättra livet för personer som lever med primär hyperoxaluri, meddelar idag att de första patienterna har fullföljt sin medverkan i en klinisk fas 3-prövning av läkemedelskandidaten Oxabact® och gått vidare till en öppen förlängningsstudie. Kirsti Gjellan is new board member of OxThera as of 19 May 2020. “It is my pleasure to welcome Kirsti to the board of OxThera”, said Dr. Georges Gemayel, Chairm Kontaktuppgifter till OxThera AB STOCKHOLM, adress, telefonnummer, se information om företaget.


Frågor att ställa mäklaren
esa grönberg

OxThera AB - Företagsupplysningen

OxThera 2006 –nu 15 år.